Stockholm, 16 August 2016. Nuevolution AB (publ) (NUE.ST) will present preclinical data from its RORƴt inverse agonist program at ICI 2016 (International Congress of Immunology) in Melbourne, Australia, on Monday 22 August. The oral presentation by Søren Jensby Nielsen, Director of Biology, Nuevolution, is titled “3291: A small-molecule preclinical candidate targeting RORγt shows a benign safety profile and effectively reduces clinical scoring and biomarker levels in mouse disease models.” The abstract will be made available on www.nuevolution.com following the oral presentation. More information about ICI 2016 can be found on http://ici2016.org/. For more information, please contact: Alex Haahr Gouliaev, CEO Phone: +45 7020 0987 Email: ahg@nuevolution.com Henrik D. Simonsen, CFO Phone: +45 3913 0947 Email: hs@nuevolution.com About Nuevolution Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno -oncology. Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Tuesday 16 August 2016, 13:00 (CET). Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com
Presentation of preclinical data from RORƴt inverse agonist program at ICI 2016
| Source: Nuevolution AB
Attachments
